177 related articles for article (PubMed ID: 26825625)
1. Laboratory evaluation of patients with undiagnosed bleeding disorders.
Alves GS; Orsi FA; Santiago-Bassora FD; Quaino SK; Montalvão SA; Paula EV; Annichino-Bizzacchi JM
Blood Coagul Fibrinolysis; 2016 Jul; 27(5):500-5. PubMed ID: 26825625
[TBL] [Abstract][Full Text] [Related]
2. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.
Agren A; Wiman B; Schulman S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):657-60. PubMed ID: 17890953
[TBL] [Abstract][Full Text] [Related]
3. Assessment of fibrinolytic activity by measuring the lysis time of a tissue-factor-induced clot: a feasibility evaluation.
Cellai AP; Lami D; Magi A; Liotta AA; Rogolino A; Antonucci E; Bandinelli B; Abbate R; Prisco D
Clin Appl Thromb Hemost; 2010 Jun; 16(3):337-44. PubMed ID: 19117964
[TBL] [Abstract][Full Text] [Related]
4. No increased systemic fibrinolysis in women with heavy menstrual bleeding.
Wiewel-Verschueren S; Knol HM; Lisman T; Bogchelman DH; Kluin-Nelemans JC; van der Zee AG; Mulder AB; Meijer K
J Thromb Haemost; 2014 Sep; 12(9):1488-93. PubMed ID: 24954113
[TBL] [Abstract][Full Text] [Related]
5. Four cases of bleeding diathesis in children due to congenital plasminogen activator inhibitor-1 deficiency.
Minowa H; Takahashi Y; Tanaka T; Naganuma K; Ida S; Maki I; Yoshioka A
Haemostasis; 1999; 29(5):286-91. PubMed ID: 10754381
[TBL] [Abstract][Full Text] [Related]
6. Increased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case-control study.
Szczepaniak P; Zabczyk M; Undas A
PLoS One; 2015; 10(4):e0125069. PubMed ID: 25909989
[TBL] [Abstract][Full Text] [Related]
7. Bidirectional functions of thrombin on fibrinolysis: Evidence of thrombin-dependent enhancement of fibrinolysis provided by spontaneous plasma clot lysis.
Tomczyk M; Suzuki Y; Sano H; Brzoska T; Tanaka H; Urano T
Thromb Res; 2016 Jul; 143():28-33. PubMed ID: 27179129
[TBL] [Abstract][Full Text] [Related]
8. Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes.
Agren A; Jörneskog G; Elgue G; Henriksson P; Wallen H; Wiman B
Diabetes Care; 2014 Jul; 37(7):2007-14. PubMed ID: 24760258
[TBL] [Abstract][Full Text] [Related]
9. Carbon monoxide-releasing molecule-2 decreases fibrinolysis in human plasma.
Nielsen VG; Kirklin JK; George JF
Blood Coagul Fibrinolysis; 2009 Sep; 20(6):448-55. PubMed ID: 19581800
[TBL] [Abstract][Full Text] [Related]
10. Variable Resistance to Plasminogen Activator Initiated Fibrinolysis for Intermediate-Risk Pulmonary Embolism.
Stubblefield WB; Alves NJ; Rondina MT; Kline JA
PLoS One; 2016; 11(2):e0148747. PubMed ID: 26866684
[TBL] [Abstract][Full Text] [Related]
11. Fibrinolysis system in patients with bronchial asthma.
Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
[TBL] [Abstract][Full Text] [Related]
12. Coagulofibrinolytic changes in patients with disseminated intravascular coagulation associated with post-cardiac arrest syndrome--fibrinolytic shutdown and insufficient activation of fibrinolysis lead to organ dysfunction.
Wada T; Gando S; Mizugaki A; Yanagida Y; Jesmin S; Yokota H; Ieko M
Thromb Res; 2013 Jul; 132(1):e64-9. PubMed ID: 23726093
[TBL] [Abstract][Full Text] [Related]
13. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
Konieczynska M; Fil K; Bazanek M; Undas A
Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
[TBL] [Abstract][Full Text] [Related]
14. Altered plasma fibrin clot properties in essential thrombocythemia.
Małecki R; Gacka M; Kuliszkiewicz-Janus M; Jakobsche-Policht U; Kwiatkowski J; Adamiec R; Undas A
Platelets; 2016; 27(2):110-6. PubMed ID: 25989112
[TBL] [Abstract][Full Text] [Related]
15. Factor XIII and tranexamic acid but not recombinant factor VIIa attenuate tissue plasminogen activator-induced hyperfibrinolysis in human whole blood.
Dirkmann D; Görlinger K; Gisbertz C; Dusse F; Peters J
Anesth Analg; 2012 Jun; 114(6):1182-8. PubMed ID: 22104068
[TBL] [Abstract][Full Text] [Related]
16. The in-vitro effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor on clot formation and susceptibility to tissue plasminogen activator-induced fibrinolysis in hemodilution model.
Shenkman B; Livnat T; Lubetsky A; Tamarin I; Budnik I; Einav Y; Martinowitz U
Blood Coagul Fibrinolysis; 2012 Jul; 23(5):370-8. PubMed ID: 22498982
[TBL] [Abstract][Full Text] [Related]
17. Thrombin-generating potential, plasma clot formation, and clot lysis are impaired in patients with bleeding of unknown cause.
Hofer S; Ay C; Rejtö J; Wolberg AS; Haslacher H; Koder S; Pabinger I; Gebhart J
J Thromb Haemost; 2019 Sep; 17(9):1478-1488. PubMed ID: 31177606
[TBL] [Abstract][Full Text] [Related]
18. [Parameters related to fibrinolysis and their meanings].
Urano T; Suzuki Y
Rinsho Byori; 2011 Jul; 59(7):703-8. PubMed ID: 21874797
[TBL] [Abstract][Full Text] [Related]
19. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.
Schleef RR; Higgins DL; Pillemer E; Levitt LJ
J Clin Invest; 1989 May; 83(5):1747-52. PubMed ID: 2496147
[TBL] [Abstract][Full Text] [Related]
20. Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome.
Van Geet C; Proesmans W; Arnout J; Vermylen J; Declerck PJ
Kidney Int; 1998 Oct; 54(4):1324-30. PubMed ID: 9767551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
